*2.5. Immunotherapy*

SLIT was performed using allergen medicines currently authorized and marketed in Italy (Oralvac Plus®/Allergy Therapeutics; Sulgen®/Roxall-Aristegui; SlitONE Ultra®, Grazax®, Accarizax®/ALK Abellò; Lais®/Lofarma). The allergen(s) used for immunotherapy (dominant allergen(s)) had to be clinically relevant to the patient's clinical history, and it was identified according to the result of SPT and specific IgE assay. In detail, a difference of wheal diameter ≥5 mm compared to the other allergen tested at SPT and a difference of half a logarithm of the IgE level for a specific allergen compared to the other allergens was required to identify the dominant allergen(s). When applicable, the awareness of the major allergens was increased using CRD. Patients with one dominant allergen underwent a single-allergen SLIT; those with two dominant allergens underwent a two-allergen SLIT (Table 3). The evaluating physicians performed the first SLIT administration, then the patients were carefully instructed about the self-administration, and written instructions were provided to follow administration protocol.


**Table 3.** Allergen(s) used for sublingual immunotherapy (SLIT).
